Contribution from the top five therapies stood at 58% of IPM in October 2021. These therapies are cardiac, anti-infectives, gastro-intestinal, anti-diabetic and vitamins
Launching in 2022, its availability will be expanded to the global market
The Lucent 3D Lumbar Interbody System features a functionally unique multi-component device manufactured in a 3D printing sequence
Venus Remedies has reported consolidated financial results for the period ended September 30, 2021
This approval of shelf-life extension was based on the availability of additional stability data, which was submitted to CDSCO
Acute therapies continue to report strong growth compared to chronic ones.
The interim analysis showed that the MVC-COV1901 vaccine has a good safety profile and elicits promising neutralising antibody titres
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
The injection is used to reverse the effects of the muscle relaxants given to patients during surgery
More than 90,000 patients utilise the services daily
Subscribe To Our Newsletter & Stay Updated
